XENE · Company research
Xenon Pharmaceuticals Inc (XENE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Vesting adds 7,500 shares for Xenon Pharmaceuticals (XENE) CFO; direct holdings total 22,500. - Stock Titan | Vesting adds 7,500 shares for Xenon Pharmaceuticals (XENE) CFO; direct holdings total 22,500. Stock Titan | View source ↗ | Stock Titan | Oct 17, 2026 | neutral | 0 | 0.6 |
| XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? | Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bearish | -0.333 | 1 |
| XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? | Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bearish | -0.333 | 1 |
| XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? - Eastern Progress | XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? Eastern Progress | View source ↗ | Eastern Progress | Oct 15, 2026 | neutral | 0 | 0.6 |
| XENE Jan 2028 60.000 call (XENE280121C00060000) Stock Price, News, Quote & History - Yahoo! Finance Canada | XENE Jan 2028 60.000 call (XENE280121C00060000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 14, 2026 | neutral | 0 | 0.6 |
| XENE Nov 2026 30.000 put (XENE261120P00030000) Stock Price, News, Quote & History - Yahoo! Finance Canada | XENE Nov 2026 30.000 put (XENE261120P00030000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 12, 2026 | neutral | 0 | 0.6 |
| Xenon Pharmaceuticals Inc Stock Warning Signs | MEX:XENE N - GuruFocus | Xenon Pharmaceuticals Inc Stock Warning Signs | MEX:XENE N GuruFocus | View source ↗ | GuruFocus | Oct 11, 2026 | neutral | 0 | 0.6 |
| Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline - Yahoo Finance | Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now - Yahoo Finance | Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Eight new Xenon employees get options to buy shares at $38.93 - Stock Titan | Eight new Xenon employees get options to buy shares at $38.93 Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ) - Seeking Alpha | Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 1, 2026 | neutral | 0 | 0.6 |
| Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month - Stocktwits | Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month Stocktwits | View source ↗ | Stocktwits | Sep 30, 2026 | neutral | 0 | 0.6 |
| Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) - PR Newswire | Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) PR Newswire | View source ↗ | PR Newswire | Sep 22, 2026 | neutral | 0 | 0.6 |
| Xenon will present a drug being developed for epilepsy and two types of depression - Stock Titan | Xenon will present a drug being developed for epilepsy and two types of depression Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Why This Biotech Just Erased Its One-Day 50% Pop - Investor's Business Daily | Why This Biotech Just Erased Its One-Day 50% Pop Investor's Business Daily | View source ↗ | Investor's Business Daily | Sep 18, 2026 | neutral | 0 | 0.6 |
| Biggest stock movers Friday: Crypto stocks, NFLX, XENE, and more - Seeking Alpha | Biggest stock movers Friday: Crypto stocks, NFLX, XENE, and more Seeking Alpha | View source ↗ | Seeking Alpha | Sep 18, 2026 | neutral | 0 | 0.6 |
| Stocks making the biggest moves premarket: Netflix, Nucor, Xenon Pharmaceuticals & more - CNBC | Stocks making the biggest moves premarket: Netflix, Nucor, Xenon Pharmaceuticals & more CNBC | View source ↗ | CNBC | Sep 18, 2026 | neutral | 0 | 0.6 |
| XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial - Barchart.com | XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial Barchart.com | View source ↗ | Barchart.com | Sep 18, 2026 | neutral | 0 | 0.6 |
| Xenon Pharmaceuticals (XENE) Stock Looks Fully Priced As Pipeline Hopes Carry Weight - Simply Wall Street | Xenon Pharmaceuticals (XENE) Stock Looks Fully Priced As Pipeline Hopes Carry Weight Simply Wall Street | View source ↗ | Simply Wall Street | Sep 16, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.